Trial Profile

A Phase 1 Study of XmAb5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafasitamab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; First in man
Sponsors Xencor

Most Recent Events

21 Jun 2020 Results, of sub-analysis assessing CD19 expression data before and after cessation of tafasitamab treatment, presented at the 25th Congress of the European Haematology Association
25 Mar 2015 According to a MorphoSys media release, results from this trial were presented at the Annual Meeting of the American Society of Hematology.
07 Dec 2014 Final results published in a MorphoSys Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com